HOME
Search 2003 Abstracts

Return to Table of Contents

388

THE EFFECT OF ANGIOTENSIN RECEPTOR BLOCKER EPROSARTAN MESYLATE ON PULSE PRESSURE IN THE TREATMENT OF ISOLATED SYSTOLIC HYPERTENSION

RJ Shanlin Reiz, I Teitelbaum, M Chilvers

Toronto, Ontario

OBJECTIVES: To assess the efficacy of eprosartan (E) 600 mg od and the effect of Home Blood Pressure Monitoring (HM) in reducing sitting blood pressure (BP). Post-hoc analysis was done to assess the effect of E on BP and pulse pressure (PP) in isolated systolic hypertension (ISH) vs non-ISH patients (pts).

METHODS: Two hundred pts (60-84 yrs) with systolic BP (SBP) of 140-179 mmHg and diastolic BP (DBP) £109 mmHg, newly diagnosed, or
previously treated but not controlled and/or intolerant to their current antihypertensive treatment were randomized to 10 weeks of E alone, or E with the use of an HM device (E+HMD). Hydrochlorothiazide (HCTZ) 12.5 mg od could be added at Week 4 or 6. For this post-hoc evaluation, pts were divided into 2 groups: ISH (baseline SBP
³ 140 and DBP < 90 mmHg) (n=97) vs. non-ISH (baseline SBP ³ 140 and DBP ³ 90 mmHg) (n=98).

RESULTS: E alone, or in combination with HCTZ (37%), reduced SBP at study endpoint by –17.5 ± 14.5 and –20.6 ± 14.1 mmHg, and DBP by –5.0 ± 7.9 and –12.2 ± 8.1 mmHg (P<0.0001 from baseline, t-test) in the ISH vs non-ISH pts, respectively, (SBP, P>0.05; DBP, P<0.0001 between groups, ANOVA model). There was no significant difference in the use of HCTZ between the ISH and non-ISH groups. At end of study, SBP was reduced by ³ 20 mmHg or to < 140 mmHg in 59% and 63% of pts in the ISH vs non-ISH groups. DBP was reduced by ³ 10 mmHg or to < 90 mmHg in 84% of non-ISH pts. Mean baseline PP was 76.0 ± 10.4 and 66.5 ± 10.0 mmHg (P<0.0001, ANOVA model), and was reduced from baseline at study endpoint by –12.5 ± 12.3 and ³8.4 ±11.1 mmHg in the ISH vs non-ISH groups (P<0.05, between groups, ANOVA model). The most common adverse events were mild dizziness, headache and fatigue.

CONCLUSIONS: E was effective in lowering sitting BP in both ISH and non-ISH pts with the magnitude of PP reduction being significantly greater in ISH pts. E was found to be well tolerated and safe. These data suggest that E may be especially suitable in the treatment of pts with ISH.

DC

NEXT